Eric G. Marcusson

8.1k total citations · 2 hit papers
47 papers, 4.9k citations indexed

About

Eric G. Marcusson is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Eric G. Marcusson has authored 47 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 23 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Eric G. Marcusson's work include MicroRNA in disease regulation (18 papers), RNA Interference and Gene Delivery (15 papers) and Circular RNAs in diseases (9 papers). Eric G. Marcusson is often cited by papers focused on MicroRNA in disease regulation (18 papers), RNA Interference and Gene Delivery (15 papers) and Circular RNAs in diseases (9 papers). Eric G. Marcusson collaborates with scholars based in United States, Denmark and Japan. Eric G. Marcusson's co-authors include Scott D. Emr, Joan Lin Cereghino, Nicholas M. Dean, Balkrishen Bhat, Bruce Horazdovsky, Editte Gharakhanian, Matthew Seaman, Elizabeth Pan, Robert A. Weinberg and George W. Bell and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Eric G. Marcusson

47 papers receiving 4.8k citations

Hit Papers

MicroRNA-143 Regulates Adipocyte Differentiation 2004 2026 2011 2018 2004 2010 250 500 750

Peers

Eric G. Marcusson
Min Sup Song United States
Thomas F. Westbrook United States
Chen‐Yong Lin United States
Monica Venere United States
Michael D. Hogarty United States
Duonan Yu China
Elena V. Ivanova United States
Min Sup Song United States
Eric G. Marcusson
Citations per year, relative to Eric G. Marcusson Eric G. Marcusson (= 1×) peers Min Sup Song

Countries citing papers authored by Eric G. Marcusson

Since Specialization
Citations

This map shows the geographic impact of Eric G. Marcusson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric G. Marcusson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric G. Marcusson more than expected).

Fields of papers citing papers by Eric G. Marcusson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric G. Marcusson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric G. Marcusson. The network helps show where Eric G. Marcusson may publish in the future.

Co-authorship network of co-authors of Eric G. Marcusson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric G. Marcusson. A scholar is included among the top collaborators of Eric G. Marcusson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric G. Marcusson. Eric G. Marcusson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martín‐Orozco, Natalia, Noah Vale, Lawrence T. Reiter, et al.. (2023). Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Scientific Reports. 13(1). 8557–8557. 5 indexed citations
2.
Halle, Bo, Eric G. Marcusson, Charlotte Aaberg-Jessen, et al.. (2015). Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. Journal of Neuro-Oncology. 126(1). 47–55. 22 indexed citations
3.
Hogan, Daniel J., Thomas M. Vincent, Sarah Fish, et al.. (2014). Anti-miRs Competitively Inhibit microRNAs in Argonaute Complexes. PLoS ONE. 9(7). e100951–e100951. 39 indexed citations
4.
Jin, Lianjin, Oliver Wessely, Eric G. Marcusson, et al.. (2013). Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/ Neu , EGF, and TNF-α in Breast Cancer. Cancer Research. 73(9). 2884–2896. 150 indexed citations
5.
Carrasco, Rosa A., Nancy B. Stamm, Eric G. Marcusson, et al.. (2011). Antisense Inhibition of Survivin Expression as a Cancer Therapeutic. Molecular Cancer Therapeutics. 10(2). 221–232. 102 indexed citations
6.
Lin, Rui, Chris Black, Andrew T. Watt, et al.. (2011). Control of RNA processing by a large non-coding RNA over-expressed in carcinomas. FEBS Letters. 585(4). 671–676. 69 indexed citations
7.
Elyakim, Eran, Einat Sitbon, Alexander Faerman, et al.. (2010). hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy. Cancer Research. 70(20). 8077–8087. 126 indexed citations
8.
Reinhardt, Ferenc, Elizabeth Pan, Jürgen Soutschek, et al.. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. PMC. 33 indexed citations
9.
Ma, Li, Ferenc Reinhardt, Elizabeth Pan, et al.. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology. 28(4). 341–347. 608 indexed citations breakdown →
10.
Segura, Miguel F., Avital Gaziel‐Sovran, Sílvia Menéndez, et al.. (2010). Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 30(12). 1481–1488. 86 indexed citations
11.
Kim, Youngsoo, Joon Won Yoon, Xiaokun Xiao, et al.. (2007). Selective Down-Regulation of Glioma-Associated Oncogene 2 Inhibits the Proliferation of Hepatocellular Carcinoma Cells. Cancer Research. 67(8). 3583–3593. 91 indexed citations
12.
Nannuru, Kalyan C., Mitsuru Futakuchi, Thomas J. Wilson, et al.. (2007). Up-regulation of soluble RANKL at tumor-bone interface is critical for mammary tumor-induced osteolysis. Cancer Research. 67. 2795–2795. 2 indexed citations
13.
Low, Jonathan, Shuguang Huang, Michele Dowless, et al.. (2007). High-Content Imaging Analysis of the Knockdown Effects of Validated siRNAs and Antisense Oligonucleotides. SLAS DISCOVERY. 12(6). 775–788. 14 indexed citations
14.
Perera, Ranjan J., Eric G. Marcusson, Seongjoon Koo, et al.. (2005). Identification of novel PPARγ target genes in primary human adipocytes. Gene. 369. 90–99. 55 indexed citations
15.
Esau, Christine, Xiaolin Kang, Eigen Peralta, et al.. (2004). MicroRNA-143 Regulates Adipocyte Differentiation. Journal of Biological Chemistry. 279(50). 52361–52365. 831 indexed citations breakdown →
16.
Michels, Jorg, Jason O’Neill, Fay Habens, et al.. (2004). Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 23(28). 4818–4827. 122 indexed citations
17.
Marcusson, Eric G., Bruce Yacyshyn, William Shanahan, & Nicholas M. Dean. (1999). Preclinical and Clinical Pharmacology of Antisense Oligonucleotides. Molecular Biotechnology. 12(1). 1–12. 30 indexed citations
18.
Cereghino, Joan Lin, Eric G. Marcusson, & Scott D. Emr. (1995). The cytoplasmic tail domain of the vacuolar protein sorting receptor Vps10p and a subset of VPS gene products regulate receptor stability, function, and localization.. Molecular Biology of the Cell. 6(9). 1089–1102. 139 indexed citations
19.
Marcusson, Eric G., Bruce Horazdovsky, Joan Lin Cereghino, Editte Gharakhanian, & Scott D. Emr. (1994). The sorting receptor for yeast vacuolar carboxypeptidase Y is encoded by the VPS10 gene. Cell. 77(4). 579–586. 421 indexed citations
20.
Schnaper, Harold W., Suzanne B. Merrill, Eric G. Marcusson, et al.. (1992). Early occurrence of end-stage renal disease in a patient with infantile nephropathic cystinosis. The Journal of Pediatrics. 120(4). 575–578. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026